ZAVZPRET 10 MG NASAL SPRAY
FDA nonproprietary name: zavegepant
For 1 unit (EA)
Pharmacies pay
$189.80 filed
1 × $189.80062 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$177.46 filed
1 × $177.45654 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.93× estimated
Medicare paid 7% less than pharmacies pay.
Part D averages every strength and form sold under “Zavzpret” / “Zavegepant HCl” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$223.27 estimated
$189.80 + $28.47 (15%) + $5.00 fee per fill = $223.27
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
ZAVZPRET 10 MG NASAL SPRAY is how the CMS NADAC file names this product. The FDA NDC Directory lists it as zavegepant, under the trade name “ZAVZPRET”.
FDA gives its dosage form as spray and its route as nasal.
The labeler, the company named on the label, is Pfizer Laboratories Div Pfizer Inc.
FDA’s Established Pharmacologic Class for it is Calcitonin Gene-related Peptide Receptor Antagonist.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00069-3500-02.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $189.80 for 1 unit (EA) (1 × $189.80062 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
What NADAC measures · NADAC explanation codes
The NDC
- 00069-3500-02 · Pfizer Laboratories Div Pfizer Inc · $189.80062 per EA · eff. 2026-09-23 filed
Compared with its class
Its NADAC price is $189.80062 per EA filed.
Of the 6 other products in FDA’s Calcitonin Gene-related Peptide Receptor Antagonist class priced per EA, 0 have a higher middle NADAC price and 6 a lower one. The one in the middle is QULIPTA 60 MG TABLET, at $38.44941 per EA filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $177.46 for 1 unit (EA), at an average of $177.45654 per EA in 2024 (2024-01-01 to 2024-12-31) for “Zavzpret” and “Zavegepant HCl”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 7,727 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for ZAVZPRET 10 MG NASAL SPRAY labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Zavzpret / Zavegepant HCl: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.
- Why does this page start at 1 unit (EA)?
- NADAC prices this product per EA, and the FDA NDC Directory lists its NDC as dosage form “SPRAY” with route “NASAL”. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and this is not one. NADAC’s EA for it may be a whole package (such as a kit, pen, syringe, vial or inhaler) or one dose inside it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.